ArticleGut2021

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Nicholas A Kennedy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.